Extracellular matrix components in breast cancer progression and metastasis

Breast

Volumn 22, Issue S2, 2013, Pages

  Oskarsson, Thordur ^a,b  

^a Heidelberg Institute for Stem Cell Technology and Experimental Medicine   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Extracellular matrix; Mammary gland involution; Metastatic breast cancer; Metastatic niche; Therapy resistance; Tissue remodeling

Indexed keywords

CATHEPSIN; CATHEPSIN K INHIBITOR; DOXORUBICIN; GELATINASE A; GELATINASE B; HYALURONIC ACID; HYMECROMONE; INTERLEUKIN 2; KALININ; LAMININ; LAMININ 10; LAMININ 111; MATRIX METALLOPROTEINASE 14; OSTEONECTIN; OSTEOPONTIN; PACLITAXEL; PROTEIN LYSINE 6 OXIDASE; STROMELYSIN; TENASCIN; THROMBOSPONDIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BASEMENT MEMBRANE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; DISEASE ASSOCIATION; ENZYME MODIFICATION; EXTRACELLULAR MATRIX; HUMAN; INVOLUTION; MAMMARY GLAND; METASTASIS; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE REMODELING; TUMOR MICROENVIRONMENT;

EXTRACELLULAR MATRIX; MAMMARY GLAND INVOLUTION; METASTATIC BREAST CANCER; METASTATIC NICHE; THERAPY RESISTANCE; TISSUE REMODELING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; REACTIVE OXYGEN SPECIES; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84884709908     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.012     Document Type: Article

References (104)

1. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
2. Muschler J., Streuli C.H. Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harbor Perspectives in Biology 2010, 2:a003202.
3. DuFort C.C., Paszek M.J., Weaver V.M. Balancing forces: architectural control of mechanotransduction. Nature Reviews Molecular Cell Biology 2011, 12:308-319.
4. Chong H.C., Tan C.K., Huang R.L., Tan N.S. Matricellular proteins: a sticky affair with cancers. Journal of Oncology 2012, 2012:351089.
5. Gudjonsson T., Ronnov-Jessen L., Villadsen R., Rank F., Bissell M.J., Petersen O.W. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. Journal of Cell Science 2002, 115:39-50.
6. Lee Y.J., Hsu T.C., Du J.Y., et al. Extracellular matrix controls insulin signaling in mammary epithelial cells through the RhoA/Rok pathway. Journal of Cellular Physiology 2009, 220:476-484.
7. Edwards G.M., Wilford F.H., Liu X., Hennighausen L., Djiane J., Streuli C.H. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. Journal of Biological Chemistry 1998, 273:9495-9500.
8. Streuli C.H., Schmidhauser C., Bailey N., et al. Laminin mediates tissue-specific gene expression in mammary epithelia. Journal of Cell Biology 1995, 129:591-603.
9. Streuli C.H., Edwards G.M., Delcommenne M., et al. Stat5 as a target for regulation by extracellular matrix. Journal of Biological Chemistry 1995, 270:21639-21644.
10. Naylor M.J., Li N., Cheung J., et al. Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. Journal of Cell Biology 2005, 171:717-728.
11. Schedin P., O'Brien J., Rudolph M., Stein T., Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. Journal of Mammary Gland Biology and Neoplasia 2007, 12:71-82.
12. O'Brien J.H., Vanderlinden L.A., Schedin P.J., Hansen K.C. Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis. Journal of Proteome Research 2012, 11:4894-4905.
13. Lyons T.R., O'Brien J., Borges V.F., et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature Medicine 2011, 17:1109-1115.
14. Bemis L.T., Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Research 2000, 60:3414-3418.
15. McDaniel S.M., Rumer K.K., Biroc S.L., et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. American Journal of Pathology 2006, 168:608-620.
16. Schedin P. Pregnancy-associated breast cancer and metastasis. Nature Reviews Cancer 2006, 6:281-291.
17. O'Brien J., Lyons T., Monks J., et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. American Journal of Pathology 2010, 176:1241-1255.
18. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nature Reviews Cancer 2009, 9:239-252.
19. Lochter A., Bissell M.J. Involvement of extracellular matrix constituents in breast cancer. Seminars in Cancer Biology 1995, 6:165-173.
20. Sheng Z., Sun W., Smith E., Cohen C., Xu X.X. Restoration of positioning control following disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000, 19:4847-4854.
21. Schenk S., Hintermann E., Bilban M., et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. Journal of Cell Biology 2003, 161:197-209.
22. Kim B.G., Gao M.Q., Choi Y.P., et al. Invasive breast cancer induces laminin-332 upregulation and integrin beta4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during tissue remodeling. Breast Cancer Research: BCR 2012, 14:R88.
23. Kwon S.Y., Chae S.W., Wilczynski S.P., Arain A., Carpenter, Philip M. Laminin 332 expression in breast carcinoma. Applied Immunohistochemistry & Molecular Morphology: AIMM/Official Publication of the Society for Applied Immunohistochemistry 2012, 20:159-164.
24. Carpenter P.M., Dao A.V., Arain Z.S., et al. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Molecular Cancer Research: MCR 2009, 7:462-475.
25. Pouliot N., Kusuma N. Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis. Cell Adhesion & Migration 2013, 7:142-149.
26. Kusuma N., Denoyer D., Eble J.A., et al. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. International Journal of Cancer. Journal International du Cancer 2012, 130:555-566.
27. Turley E.A., Noble P.W., Bourguignon L.Y. Signaling properties of hyaluronan receptors. Journal of Biological Chemistry 2002, 277:4589-4592.
28. Auvinen P., Tammi R., Kosma V.M., et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. International Journal of Cancer. Journal International du Cancer 2013, 132:531-539.
29. Okuda H., Kobayashi A., Xia B., et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Research 2012, 72:537-547.
30. Li Y., Li L., Brown T.J., Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. International Journal of Cancer. Journal International du Cancer 2007, 120:2557-2567.
31. Udabage L., Brownlee G.R., Waltham M., et al. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Research 2005, 65:6139-6150.
32. Hamilton S.R., Fard S.F., Paiwand F.F., et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. Journal of Biological Chemistry 2007, 282:16667-16680.
33. Maquoi E., Assent D., Detilleux J., Pequeux C., Foidart J.M., Noel A. MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. Oncogene 2012, 31:480-493.
34. Sternlicht M.D., Lochter A., Sympson C.J., et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
35. Ha H.Y., Moon H.B., Nam M.S., et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Research 2001, 61:984-990.
36. Look M.P., van Putten W.L., Duffy M.J., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of the National Cancer Institute 2002, 94:116-128.
37. Withana N.P., Blum G., Sameni M., et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Research 2012, 72:1199-1209.
38. Victor B.C., Anbalagan A., Mohamed M.M., Sloane B.F., Cavallo-Medved D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Research: BCR 2011, 13:R115.
39. Vasiljeva O., Papazoglou A., Kruger A., et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research 2006, 66:5242-5250.
40. Le Gall C., Bellahcene A., Bonnelye E., et al. Acathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Research 2007, 67:9894-9902.
41. Erler J.T., Bennewith K.L., Nicolau M., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
42. Levental K.R., Yu H., Kass L., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
43. Orend G., Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Letters 2006, 244:143-163.
44. Tsunoda T., Inada H., Kalembeyi I., et al. Involvement of large tenascin-C splice variants in breast cancer progression. American Journal of Pathology 2003, 162:1857-1867.
45. Oskarsson T., Acharyya S., Zhang X.H., et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Medicine 2011, 17:867-874.
46. Tavazoie S.F., Alarcon C., Oskarsson T., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
47. Ilunga K., Nishiura R., Inada H., et al. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion. International Journal of Experimental Pathology 2004, 85:373-379.
48. Hancox R.A., Allen M.D., Holliday D.L., et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Research: BCR 2009, 11:R24.
49. Jahkola T., Toivonen T., Virtanen I., et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. British Journal of Cancer 1998, 78:1507-1513.
50. Yoshida T., Ishihara A., Hirokawa Y., Kusakabe M., Sakakura T. Tenascin in breast cancer development - is epithelial tenascin a marker for poor prognosis?. Cancer Letters 1995, 90:65-73.
51. Ishihara A., Yoshida T., Tamaki H., Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1995, 1:1035-1041.
52. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Current Molecular Medicine 2010, 10:71-81.
53. Noti J.D. Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. International Journal of Oncology 2000, 17:1237-1243.
54. Oates A.J., Barraclough R., Rudland P.S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996, 13:97-104.
55. Tuck A.B., Arsenault D.M., O'Malley F.P., et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
56. Tuck A.B., O'Malley F.P., Singhal H., et al. Osteopontin expression in a group of lymph node negative breast cancer patients. International Journal of Cancer. Journal International du Cancer 1998, 79:502-508.
57. Tuck A.B., O'Malley F.P., Singhal H., et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Archives of Pathology & Laboratory Medicine 1997, 121:578-584.
58. Singhal H., Bautista D.S., Tonkin K.S., et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1997, 3:605-611.
59. Bramwell V.H., Doig G.S., Tuck A.B., et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12:3337-3343.
60. McAllister S.S., Gifford A.M., Greiner A.L., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
61. Morra L., Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Archiv: An International Journal of Pathology 2011, 459:465-475.
62. Maruhashi T., Kii I., Saito M., Kudo A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase. Journal of Biological Chemistry 2010, 285:13294-13303.
63. Malanchi I., Santamaria-Martinez A., Susanto E., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
64. Sasaki H., Yu C.Y., Dai M., et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Research and Treatment 2003, 77:245-252.
65. Barth P.J., Moll R., Ramaswamy A. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Archiv: An International Journal of Pathology 2005, 446:532-536.
66. Gilles C., Bassuk J.A., Pulyaeva H., Sage E.H., Foidart J.M., Thompson E.W. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Research 1998, 58:5529-5536.
67. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
68. Park S.Y., Lee H.E., Li H., Shipitsin M., Gelman R., Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:876-887.
69. Graham J.D., Balleine R.L., Milliken J.S., Bilous A.M., Clarke C.L. Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. European Journal of Cancer 1997, 33:1654-1660.
70. Witkiewicz A.K., Freydin B., Chervoneva I., et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biology & Therapy 2010, 10:391-396.
71. Hsiao Y.H., Lien H.C., Hwa H.L., Kuo W.H., Chang K.J., Hsieh F.J. SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast Journal 2010, 16:305-308.
72. Helleman J., Jansen M.P., Ruigrok-Ritstier K., et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:5555-5564.
73. Lopez-Dee Z., Pidcock K., Gutierrez L.S. Thrombospondin-1: multiple paths to inflammation. Mediators of Inflammation 2011, 2011:296069.
74. Albo D., Berger D.H., Wang T.N., Hu X., Rothman V., Tuszynski G.P. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997, 122:493-499. [discussion 99-500].
75. Martin-Manso G., Calzada M.J., Chuman Y., et al. sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration. Archives of Biochemistry and Biophysics 2011, 509:147-156.
76. Yee K.O., Connolly C.M., Duquette M., Kazerounian S., Washington R., Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Research and Treatment 2009, 114:85-96.
77. Fontana A., Filleur S., Guglielmi J., et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 invivo. International Journal of Cancer. Journal International du Cancer 2005, 116:686-691.
78. Suh E.J., Kabir M.H., Kang U.B., et al. Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. Experimental & Molecular Medicine 2012, 44:36-44.
79. Byrne G.J., Hayden K.E., McDowell G., et al. Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. International Journal of Oncology 2007, 31:1127-1132.
80. Nathan F.E., Hernandez E., Dunton C.J., et al. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 1994, 73:2853-2858.
81. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
82. Erler J.T., Bennewith K.L., Cox T.R., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
83. Oskarsson T., Massague J. Extracellular matrix players in metastatic niches. EMBO Journal 2012, 31:254-256.
84. Kii I., Nishiyama T., Li M., et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. Journal of Biological Chemistry 2010, 285:2028-2039.
85. Bergamaschi A., Tagliabue E., Sorlie T., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology 2008, 214:357-367.
86. Farmer P., Bonnefoi H., Anderle P., et al. Astroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine 2009, 15:68-74.
87. Pang H., Cai L., Yang Y., Chen X., Sui G., Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biotherapy & Radiopharmaceuticals 2011, 26:165-173.
88. Yang L., Wei L., Zhao W., et al. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Molecular Medicine Reports 2012, 5:373-376.
89. Said G., Guilbert M., Morjani H., Garnotel R., Jeannesson P., El Btaouri H. Extracellular matrix proteins modulate antimigratory and apoptotic effects of doxorubicin. Chemotherapy Research and Practice 2012, 2012:268681.
90. Pupa S.M., Giuffre S., Castiglioni F., et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Research 2007, 67:4271-4277.
91. Misra S., Ghatak S., Zoltan-Jones A., Toole B.P. Regulation of multidrug resistance in cancer cells by hyaluronan. Journal of Biological Chemistry 2003, 278:25285-25288.
92. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. Journal of Biological Chemistry 2005, 280:20310-20315.
93. Shree T., Olson O.C., Elie B.T., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes & Development 2011, 25:2465-2479.
94. Yang X.H., Flores L.M., Li Q., et al. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Research 2010, 70:2256-2263.
95. Cordes N., Blaese M.A., Plasswilm L., Rodemann H.P., Van Beuningen D. Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells invitro. International Journal of Radiation Biology 2003, 79:709-720.
96. Martinetti A., Bajetta E., Ferrari L., et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocrine-related Cancer 2004, 11:771-779.
97. Schafer Z.T., Grassian A.R., Song L., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
98. Acharyya S., Oskarsson T., Vanharanta S., et al. ACXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
99. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
100. Kyutoku M., Taniyama Y., Katsuragi N., et al. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. International Journal of Molecular Medicine 2011, 28:181-186.
101. Urakawa H., Nishida Y., Wasa J., et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity invitro and metastatic lesions of bone invivo. International Journal of Cancer. Journal International du Cancer 2012, 130:454-466.
102. Jensen A.B., Wynne C., Ramirez G., et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clinical Breast Cancer 2010, 10:452-458.
103. Bauerle T., Komljenovic D., Merz M., Berger M.R., Goodman S.L., Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal invivo study. International Journal of Cancer. Journal International du Cancer 2011, 128:2453-2462.
104. Marlind J., Kaspar M., Trachsel E., et al. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:6515-6524.